Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

lung cancer

  • You have access
    Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese
    MENG-FENG WU, LI-HSIOU CHEN, NING-YI HSIA, YI-CHENG SHEN, TE-CHUN SHEN, ZHI-HONG WANG, YA-CHEN YANG, YUN-CHI WANG, WEN-SHIN CHANG, TE-CHUN HSIA, DA-TIAN BAU and CHIA-WEN TSAI
    Anticancer Research July 2022, 42 (7) 3381-3387; DOI: https://doi.org/10.21873/anticanres.15825
  • Open Access
    Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System
    YUICHI HIROSHIMA, YOSHIO TAMAKI, TAKUYA SAWADA, TOSHIKI ISHIDA, KENJI YASUE, KAZUYA SHINODA, TAKASHI SAITO, TAKAYUKI KABURAGI, MORIYUKI KIYOSHIMA, TOSHIYUKI OKUMURA and HIDEYUKI SAKURAI
    Anticancer Research June 2022, 42 (6) 2989-2995; DOI: https://doi.org/10.21873/anticanres.15782
  • Open Access
    Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
    TOSHIHIRO SHIOZAWA, TAKESHI NUMATA, TOMOHIRO TAMURA, TAKEO ENDO, TAKAYUKI KABURAGI, YUSUKE YAMAMOTO, HIDEYASU YAMADA, NORIHIRO KIKUCHI, KAZUHITO SAITO, MASAHARU INAGAKI, KOICHI KURISHIMA, YASUNORI FUNAYAMA, KUNIHIKO MIYAZAKI, NOBUYUKI KOYAMA, KINYA FURUKAWA, HIROYUKI NAKAMURA, SHINJI KIKUCHI, HIDEO ICHIMURA, YUKIO SATO, IKUO SEKINE, HIROAKI SATOH and NOBUYUKI HIZAWA
    Anticancer Research May 2022, 42 (5) 2583-2590; DOI: https://doi.org/10.21873/anticanres.15736
  • You have access
    Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer
    DIRK RADES, ESTHER GLATZEL, SABINE BOHNET, STEVEN E. SCHILD and ELISA M. WERNER
    Anticancer Research April 2022, 42 (4) 1973-1977; DOI: https://doi.org/10.21873/anticanres.15675
  • You have access
    Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
    MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA and MAREK STASTNY
    Anticancer Research April 2022, 42 (4) 1987-1995; DOI: https://doi.org/10.21873/anticanres.15677
  • You have access
    A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer
    ESTHER GLATZEL, ELISA M. WERNER, SABINE BOHNET and DIRK RADES
    Anticancer Research April 2022, 42 (4) 2029-2032; DOI: https://doi.org/10.21873/anticanres.15683
  • You have access
    Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
    CHI-HAN CHEN, JOHN WEN-CHENG CHANG, CHING-FU CHANG, CHEN-YANG HUANG, CHENG-TA YANG, CHIH-HSI SCOTT KUO, YUEH-FU FANG, PING-CHIH HSU and CHIAO-EN WU
    Anticancer Research April 2022, 42 (4) 2145-2157; DOI: https://doi.org/10.21873/anticanres.15697
  • You have access
    Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma
    MASAKO YUMURA, TATSUYA NAGANO, NAOE JIMBO, RYOTA DOKUNI, TATSUNORI KIRIU, YUGO TANAKA, MOTOKO TACHIHARA, TOMOO ITOH, YOSHIMASA MANIWA, YOSHIHIRO NISHIMURA and KAZUYUKI KOBAYASHI
    Anticancer Research March 2022, 42 (3) 1289-1294; DOI: https://doi.org/10.21873/anticanres.15595
  • You have access
    Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer
    MARTIN SVATON, MARIE DROSSLEROVA, ONDREJ FISCHER, MILOSLAV MAREL, MICHAL HRNCIARIK, ONDREJ VENCLICEK, PETR ZUNA, MICHAL SVOBODA, JIRI BLAZEK, MONIKA BRATOVA, ANDREA MULLEROVA, BOHUSLAVA VANKOVA and DANIEL KREJCI
    Anticancer Research March 2022, 42 (3) 1563-1569; DOI: https://doi.org/10.21873/anticanres.15630
  • You have access
    Administration of Gapmer-type Antisense Oligonucleotides Targeting γ-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts
    HIROMI II, YUUYA KASAHARA, HARUMI YAMAGUMA, SUSUMU KAGEYAMA, AKIHIRO KAWAUCHI, SATOSHI OBIKA and SUSUMU NAKATA
    Anticancer Research March 2022, 42 (3) 1221-1227; DOI: https://doi.org/10.21873/anticanres.15589

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 22
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire